Events

All members have the option of attending our various HTC-centric events which include:

  • Two in-person member meetings a year (in spring and fall)
  • Regular Webinars educating our members on HTC operations & organizational management, payer relations, regulations and legal updates, and advocacy

🟥 Member Webinar : Hemophilia Alliance Hosts – A webinar from Takeda on FVIII Portfolio

Date: Thursday, March 20th, 2025 Time: 2:00pm - 3:00pm ET       TITLE: Takeda FVIII Portfolio OBJECTIVE: Please join Takeda leadership to review Takeda FVIII Products & Resources Available. INTENDED AUDIENCE: All HTC staff SPEAKER: Anthea Cherednichenko, VP US Hematology Franchise Head Anthea leads the sales and marketing teams for Takeda’s Hematology portfolio. Anthea Read the full article...

🟥 Member Webinar : Hemophilia Alliance Hosts – A webinar from Novo Nordisk on Alhemo (concizumab-mtci): A new option for patients living with hemophilia A or B with inhibitors

Date: Thursday, April 3rd, 2025 Time: 2:00pm - 3:00pm ET         WEBINAR TOPIC: Alhemo (concizumab-mtci): A new option for patients living with hemophilia A or B with inhibitors OBJECTIVE: To provide a prescribing information overview of the recently FDA approved medication, Alhemo (concizumab-mtci), for patients living with hemophilia A or B with Read the full article...

🟥 Member Webinar : Hemophilia Alliance Hosts – A webinar from Pfizer on Complications and challenges associated with hemophilia and a rebalancing approach with HYMPAVZI™ (marstacimab-hncq)

Date: Tuesday, May 6th, 2025 Time: 2:00pm - 3:00pm ET         WEBINAR TOPIC: Complications and challenges associated with hemophilia and a rebalancing approach with HYMPAVZI™ (marstacimab-hncq) OBJECTIVES: Educate attendees on complications and challenges associated with hemophilia, the novel mechanism of action of HYMPAVZI, the BASIS Ph3 clinical trial results and dosage and Read the full article...

🟥 Member Webinar : Hemophilia Alliance Hosts – A webinar from Sanofi – Exploring data and expert perspectives on Qfitlia™ (fitusiran)

Date: Wednesday, May 7th, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TOPIC: Exploring data and expert perspectives on Qfitlia™ (fitusiran) OBJECTIVE: During this program, we will explore data and expert perspectives on Qfitlia™ (fitusiran), a newly approved prophylactic treatment for patients with hemophilia A and B, with or without inhibitors. SPEAKER: Vanessa Read the full article...

🟥 Member Webinar : Hemophilia Alliance Hosts – A webinar from BioMarin – A Collaborative Journey – ROCTAVIAN Patient & Provider Perspectives

Date: Tuesday, May 13th, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TOPIC: A Collaborative Journey - ROCTAVIAN Patient & Provider Perspectives OBJECTIVE: Join us for an insightful webinar exploring the real-world experiences of patients and providers with ROCTAVIAN. Hear firsthand accounts of the treatment journey, from initial consultations and administration to outcomes Read the full article...

🟥 Member Webinar : Hemophilia Alliance Hosts – A webinar from Octapharma – Review The Clinical Benefits of wilate®, Highlighting The Benefits vs Current vWD Therapies

Date: Tuesday, July 22nd, 2025 Time: 1:00pm - 2:00pm ET         WEBINAR TOPIC: Review the clinical benefits of wilate®, highlighting the benefits vs current vWD therapies. OBJECTIVES: Understand the attributes of wilate® for vWD: 1:1 ratio which mimics the physiologic activity of vWF and FVIII and the synchronous decay curves, which facilitates Read the full article...

🟥 Member Webinar : Hemophilia Alliance Hosts – A Webinar From Pfizer On Subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience

Date: Wednesday, August 27th, 2025 Time: 2:00pm - 3:00pm ET           WEBINAR TITLE: Juggling Fall Routines Can Be Complicated. Help your patients keep their hemophilia treatment simple with subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience. OBJECTIVES: To educate attendees on challenges, shared decision making in hemophilia and introduce Read the full article...